PTCT
PTC THERAPEUTICS, INC.
+0.10 (+0.15%)67.69USD389K成交股數5.6B市值–本益比(近四季)5.6股價營收比+101.5%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 361M-69% | 273M+28% | 211M+7% | 179M-4% | 1.2B+460% | 213M+8% | 197M-8% | 187M-15% | 210M | 197M | 214M | 220M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 99.2M | 101M | 100M | 113M | 109M | 125M | 161M | 132M | 116M | 164M | 186M | 195M |
| 銷售管理費用 | 80.6M | 86.2M | 84.0M | 85.3M | 81.0M | 84.7M | 73.5M | 69.5M | 73.3M | 80.9M | 88.4M | 86.9M |
| 營業利益 | 149M-85% | 45.0M-128% | 3.0M-106% | −35.0M-13% | 970M-2235% | −162M+37% | −54.5M-74% | −40.2M-66% | −45.5M | −118M | −210M | −118M |
| 營業利益率 | 41.3% | 16.5% | 1.4% | -19.5% | 82.5% | -76.2% | -27.7% | -21.5% | -21.6% | -60.1% | -98.0% | -53.4% |
| 稅後淨利 | 83.5M-90% | −2.8M-96% | 15.9M-115% | −64.8M-35% | 867M-1046% | −65.9M-50% | −107M-46% | −99.2M-29% | −91.6M | −133M | −199M | −139M |
| 淨利率 | 23.2% | -1.0% | 7.5% | -36.3% | 73.7% | -30.9% | -54.2% | -53.1% | -43.6% | -67.6% | -93.0% | -63.1% |
| 稀釋 EPS | 0.92-91% | -0.03-96% | 0.20-114% | -0.83-36% | 10.04-937% | -0.85-52% | -1.39-48% | -1.29-31% | -1.20 | -1.76 | -2.66 | -1.88 |
| 稀釋股數 | 92.0M | 82.5M | 87.1M | 78.2M | 86.4M | 76.8M | 76.9M | 76.7M | 76.5M | 75.4M | 74.7M | 73.7M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 1.0B | 834M | 673M | 1.0B | 1.5B | 780M | 526M | 655M | 548M | 165M | 208M | 167M |
| 應收帳款 | 239M | 220M | 203M | 196M | 210M | 159M | 200M | 187M | 198M | 166M | 178M | 202M |
| 存貨 | 91.4M | 75.6M | 52.7M | 34.1M | 21.7M | 23.2M | 35.7M | 31.8M | 30.1M | 35.8M | 32.0M | 26.6M |
| 總資產 | 3.3B | 2.9B | 2.6B | 2.6B | 2.7B | 1.7B | 1.8B | 1.9B | 1.8B | 1.3B | 1.3B | 1.6B |
| 有息負債 | 536M | – | – | 286M | 286M | 285M | 285M | 285M | 285M | 573M | 573M | 572M |
| 總負債 | 3.4B | 3.0B | 2.8B | 2.8B | 2.8B | 2.8B | 2.9B | 2.9B | 2.7B | 1.9B | 1.9B | 2.1B |
| 股東權益 | −165M | −180M | −156M | −207M | −186M | −1.1B | −1.1B | −980M | −894M | −671M | −579M | −458M |
| 負債比 | 105.1% | 106.3% | 105.9% | 107.8% | 107.0% | 164.4% | 157.2% | 151.1% | 149.9% | 153.2% | 143.3% | 128.4% |
| 淨現金(現金 − 有息負債) | 514M | – | – | 731M | 1.2B | 494M | 241M | 370M | 264M | −408M | −364M | −405M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −59.0M | – | – | 870M+1130% | – | – | – | 70.8M | – | – | −29.5M |
| 資本支出 | – | 1.2M | – | – | 1.7M | – | – | – | 9.6M | – | – | 10.3M |
| 自由現金流 | – | −60.2M | – | – | 868M+1320% | – | – | – | 61.2M | – | – | −39.8M |
| 折舊攤銷 | – | 15.4M | – | – | 7.2M | – | – | – | 55.4M | – | – | 42.8M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -22.1% | – | – | 73.8% | – | – | – | 29.1% | – | – | -18.0% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 1.7B
| Life Science | 1.7B | 100.0% | +114.5% |
|---|
地區2025 年度 · 418M
| 美國 | 252M | 60.3% | +21.7% |
|---|---|---|---|
| RU | 100M | 24.0% | -4.7% |
| 巴西 | 65.7M | 15.7% | -8.9% |
| 美國以外 小計 | 236M | 56.4% | -40.1% |
| All Other Countries Other Than Russia Brazil And United States 小計 | 168M | 40.3% | -14.7% |
產品／服務2025 年度 · 1.7B
| Collaboration And License Revenue | 998M | 59.3% | +328306.9% |
|---|---|---|---|
| Royalty | 244M | 14.5% | +19.8% |
| Translarna1 | 235M | 14.0% | -26.7% |
| Sephience | 111M | 6.6% | – |
| Upstaza And Kebilidi | 56.6M | 3.4% | +234.8% |
| Other Products | 37.3M | 2.2% | +0.9% |
| 產品 小計 | 587M | 34.9% | +0.8% |
| Emflaza 小計 | 146M | 8.7% | -29.4% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 1.7B | +114.5% | 683M | 39.5% | 7.78 | 702M |
| FY2024 | 807M | -14.0% | −363M | -45.0% | -4.73 | −114M |
| FY2023 | 938M | +34.2% | −627M | -66.8% | -8.37 | −187M |
| FY2022 | 699M | +29.7% | −559M | -80.0% | -7.79 | −389M |
| FY2021 | 539M | +41.4% | −524M | -97.3% | -7.43 | −280M |
| FY2020 | 381M | +24.0% | −438M | -115.1% | -6.64 | −212M |
| FY2019 | 307M | +16.0% | −252M | -82.0% | -4.27 | −112M |
| FY2018 | 265M | – | −128M | -48.4% | -2.75 | −34.7M |